Latest News
-
Monday - June 17, 2013
Anniversary Song Project
150 Years of Bayer: pop song for a good cause
Employee teams from various countries record "A Better Life" » more
-
Wednesday - June 12, 2013
Commercial launch of technology from Bayer and ThyssenKrupp:
Chlorine production with much less electricity
New process reduces energy consumption by roughly one-third / Trial phase completed successfully » more
-
Wednesday - June 12, 2013
Diabetes Care:
Bayer HealthCare supports diabetes projects in the Middle East, North Africa and Europe
“Excellence across Borders” program fosters practical solutions in diabetes management to propel therapy outcome » more
-
Thursday - June 6, 2013
High-class outfit of car seats, sports and fashion goods
Bayer develops solvent-free raw materials for textile coating
Polyurethane dispersions fulfill the highest requirements » more
-
Thursday - June 6, 2013
Not intended for U.S. and UK Media - VEGF Trap-Eye in myopic choroidal neovascularization:
Positive Phase 3 Results for VEGF Trap-Eye (Intravitreal Aflibercept) in Myopic Choroidal Neovascularization (mCNV) » more
-
Wednesday - June 5, 2013
Bayer Science & Education Foundation launches new round of funding:
Bayer foundation scholarships – EUR 200,000 for work and study abroad
Support for ambitious study projects in the fields of science, engineering, medicine and teacher training in scientific subjects / Hermann Strenger scholarships to sponsor career-training projects abroad / Applications now possible online till July 15, 2013 » more
-
Wednesday - June 5, 2013
Tender offer successful:
Bayer acquires majority interest in Conceptus
96.4 percent of Conceptus’ shares tendered / Conceptus imminently to become a wholly-owned Bayer subsidiary » more
-
Sunday - June 2, 2013
Not intended for U.S. and UK Media - Results of pivotal Phase III study in differentiated thyroid cancer:
Positive Phase III Data on Sorafenib Show Significant Improvement in Progression-Free Survival Time in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer
Currently there are no approved therapies specifically for radioactive iodine refractory differentiated thyroid cancer / Sorafenib (Nexavar®) significantly extended progression-free survival; median progression-free survival of 10.8 months, compared to 5.8 months with placebo / Results from pivotal Phase III DECISION trial presented in plenary session at Annual Meeting of the American Society of Clinical Oncology » more
-
Wednesday - May 29, 2013
Antitrust clearance obtained for Bayer's acquisition of Conceptus
Offer expires at midnight on June 4/5, 2013 » more
-
Friday - May 24, 2013
Not intended for U.S. and UK Media
Bayer’s Xarelto® Approved in the EU for Secondary Prevention after an Acute Coronary Syndrome
Following an ACS event, one in ten patients will have another major atherothrombotic event (cardiovascular death, myocardial infarction or stroke) within a year / Xarelto 2.5 mg BID in combination with antiplatelet therapy can help prevent athero-thrombotic events by providing more complete protection than antiplatelet therapy alone / Xarelto is approved to protect patients from blood clots across more venous and arterial thromboembolic conditions than any other novel oral anticoagulant » more
-
Friday - May 24, 2013
European Commission’s desision a set-back for European agriculture:
Decision to restrict use of neonicotinoid-containing products will not improve bee health » more
-
Friday - May 24, 2013
2013 ISF World Seed Congress in Athens
Bayer SeedGrowth™: the fully integrated system for on-seed applications from a single source
Around 100 years of experience in the seed treatment business / In-house competence in Products, Coatings, Equipment and Services / New customer-centric website www.seedgrowth.bayer.com launched » more
-
Wednesday - May 22, 2013
Cemex Germany new cooperation partner:
Global specialist network for sustainable building grows
Over 80 specialists in Bayer-led EcoCommercial Building program » more
-
Wednesday - May 22, 2013
Johannes Schubmehl appointed CIO of Bayer HealthCare » more
-
Tuesday - May 21, 2013
Novel ideas for mobility, construction and IT:
Bayer opens Innovation Hub for Asia Pacific
More than 200 experts to be employed in Shanghai » more
-
Monday - May 20, 2013
Not intended for U.S. and UK Media - American Thoracic Society International Conference, Philadelphia, USA:
Bayer Presents Positive Interim Results from Long-term Extension Study PATENT-2 with Riociguat
Riociguat showed good long-term safety profile(1) / Riociguat demonstrated significant and sustained improvements in six minute walking distance (6MWD) and WHO functional class (FC) in patients with pulmonary arterial hypertension (PAH)(1) » more
-
Friday - May 17, 2013
Not intended for U.S. and UK Media
Bayer Submits Investigational Drug Riociguat for Patients with Chronic Thromboembolic Pulmonary Hypertension for Regulatory Approval in Japan » more
-
Thursday - May 16, 2013
Strategic move to strengthen Consumer Care business:
Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast® and Laif® brands » more
-
Thursday - May 16, 2013
Not intended for U.S. and UK Media - 49th Annual Meeting of the American Society of Clinical Oncology (ASCO):
Bayer to Present New Data Across Oncology Portfolio at ASCO 2013
First presentation of final analysis from pivotal Phase III DECISION trial of Nexavar (sorafenib) in patients with differentiated thyroid cancer presented as Plenary Abstract in Oral Abstract Session / Data presentations for three oncology products across five tumor types » more
-
Wednesday - May 15, 2013
Not intended for U.S. and UK Media
Bayer Receives U.S. FDA Approval for Cancer Treatment Xofigo® (radium 223 dichloride) Injection
New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases / Xofigo shown in a pivotal Phase III trial to significantly improve overall survival » more
Copyright @ Bayer AG